Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14939MR)

This product GTTS-WQ14939MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14939MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10509MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ285MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ11646MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ14369MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ13161MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ11959MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ13977MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ3562MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAX069
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW